ES2046083B1 - Procedimiento para preparar composiciones de liberacion prolongada. - Google Patents

Procedimiento para preparar composiciones de liberacion prolongada.

Info

Publication number
ES2046083B1
ES2046083B1 ES09101785A ES9101785A ES2046083B1 ES 2046083 B1 ES2046083 B1 ES 2046083B1 ES 09101785 A ES09101785 A ES 09101785A ES 9101785 A ES9101785 A ES 9101785A ES 2046083 B1 ES2046083 B1 ES 2046083B1
Authority
ES
Spain
Prior art keywords
procedure
prolonged release
release compositions
preparing
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09101785A
Other languages
English (en)
Spanish (es)
Other versions
ES2046083A1 (es
Inventor
Jean-Marc Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of ES2046083A1 publication Critical patent/ES2046083A1/es
Application granted granted Critical
Publication of ES2046083B1 publication Critical patent/ES2046083B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Glanulating (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES09101785A 1990-08-01 1991-07-30 Procedimiento para preparar composiciones de liberacion prolongada. Expired - Fee Related ES2046083B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909016885A GB9016885D0 (en) 1990-08-01 1990-08-01 Sustained release pharmaceutical compositions

Publications (2)

Publication Number Publication Date
ES2046083A1 ES2046083A1 (es) 1994-01-16
ES2046083B1 true ES2046083B1 (es) 1994-08-01

Family

ID=10679993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09101785A Expired - Fee Related ES2046083B1 (es) 1990-08-01 1991-07-30 Procedimiento para preparar composiciones de liberacion prolongada.

Country Status (30)

Country Link
US (1) US5213812A (show.php)
JP (1) JP2818704B2 (show.php)
KR (1) KR920003962A (show.php)
AT (1) AT396425B (show.php)
AU (2) AU649696B2 (show.php)
BE (1) BE1004772A3 (show.php)
CA (1) CA2048270C (show.php)
CH (1) CH682715A5 (show.php)
DE (1) DE4125542A1 (show.php)
DK (1) DK175756B1 (show.php)
ES (1) ES2046083B1 (show.php)
FI (1) FI104149B (show.php)
FR (1) FR2665360B1 (show.php)
GB (1) GB9016885D0 (show.php)
GR (1) GR1001512B (show.php)
HK (1) HK33294A (show.php)
IE (1) IE65124B1 (show.php)
IN (1) IN178446B (show.php)
IT (1) IT1251788B (show.php)
LU (1) LU87982A1 (show.php)
MA (1) MA22245A1 (show.php)
MY (1) MY107500A (show.php)
NL (1) NL194637C (show.php)
NO (1) NO300158B1 (show.php)
NZ (1) NZ238981A (show.php)
OA (1) OA09387A (show.php)
PT (1) PT98497B (show.php)
SE (1) SE505734C2 (show.php)
TN (1) TNSN91067A1 (show.php)
ZA (1) ZA915565B (show.php)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
EP0740548B1 (en) * 1994-02-28 2002-12-04 Nanopharm AG Drug targeting system, method for preparing same and its use
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
DE19604744A1 (de) 1996-02-09 1997-08-14 Henkel Kgaa Technische Di-/Triglyceridgemische
DE19617137C1 (de) * 1996-04-29 1997-02-27 Henkel Kgaa Verwendung von Copolymerestern für die Herstellung von Mikrosphären
EP0930874A2 (en) * 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
WO1999052708A1 (en) 1998-04-13 1999-10-21 Luminex Corporation Liquid labeling with fluorescent microparticles
ME00066B (me) * 1998-12-16 2010-06-10 Aventis Holdings Inc Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja
AU5644400A (en) * 1999-09-24 2001-03-29 Rohm And Haas Company Pellet compositions
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
WO2003015750A1 (en) * 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
FR2848113B1 (fr) * 2002-12-04 2005-02-25 Oreal Stabilisation de principes actifs aromatiques par des polymeres aromatiques
US20040166077A1 (en) * 2002-12-04 2004-08-26 L'oreal Process for treating keratin materials with aromatic active principles
US8075919B2 (en) * 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US20060135277A1 (en) * 2003-09-10 2006-06-22 Marnocha Bendict F Golf club and practice arrangement
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
EP2335689A1 (en) 2004-05-12 2011-06-22 Baxter International Inc. Method of manufacturing nucleic acid micropheres
JP5634009B2 (ja) * 2004-05-12 2014-12-03 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ タンパク質を含み、そして高濃度のタンパク質で注射性能を示すミクロスフェア
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
AU2005244851B2 (en) * 2004-05-12 2010-08-26 Baxter Healthcare S.A. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
AU2005271782A1 (en) * 2004-07-13 2006-02-16 Altairnano, Inc. Ceramic structures for controlled release of drugs
JP2008506699A (ja) * 2004-07-13 2008-03-06 アルテアーナノ，インコーポレーテッド 薬物転用防止用セラミック構造体
JP2008528443A (ja) * 2004-10-29 2008-07-31 アドヒーシブズ・リサーチ・インコーポレイテッド セキュリティ・アイデンティフィケーションのための微視的なタグ付けシステム
EP1885335A1 (en) * 2005-04-27 2008-02-13 BAXTER INTERNATIONAL INC. (a Delaware corporation) Surface-modified microparticles and methods of forming and using the same
JP2009505824A (ja) * 2005-08-23 2009-02-12 アルテアナノ インコーポレイテッド 高度な光触媒のリンドープアナターゼＴｉＯ２組成物及びその製造方法
WO2007103812A1 (en) * 2006-03-02 2007-09-13 Altairnano, Inc. Method for low temperature production of nano-structured iron oxide coatings
WO2007103829A1 (en) * 2006-03-02 2007-09-13 Altairnano, Inc. Method for production of metal oxide coatings
US20080020175A1 (en) * 2006-03-02 2008-01-24 Fred Ratel Nanostructured Indium-Doped Iron Oxide
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
AU2007281737B2 (en) * 2006-08-04 2013-09-19 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2008060786A2 (en) * 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
EP2077821B1 (en) 2006-10-12 2019-08-14 The University Of Queensland Compositions and methods for modulating immune responses
US20090169628A1 (en) * 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
US20080254258A1 (en) * 2007-04-12 2008-10-16 Altairnano, Inc. Teflon® replacements and related production methods
AU2008242842B2 (en) * 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
US9782300B2 (en) 2008-02-01 2017-10-10 Kci Licensing, Inc. Fiber-microsphere bioresorbable composite scaffold for wound healing
CA2720675C (en) 2008-04-18 2019-08-27 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US20100078848A1 (en) * 2008-09-29 2010-04-01 Armark Authentication Technologies, Llc Spinneret and method of spinning fiber
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US20100291384A1 (en) * 2009-05-15 2010-11-18 Armark Authentication Technologies, Llc Fiber having non-uniform composition and method for making same
US20110020388A1 (en) 2009-05-27 2011-01-27 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US20110076771A1 (en) * 2009-09-25 2011-03-31 Armark Authentication Technologies, Llc Tissue fiber scaffold and method for making
CN107096021A (zh) 2010-05-26 2017-08-29 西莱克塔生物科技公司 多价的合成纳米载体疫苗
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
US11311610B2 (en) 2010-11-01 2022-04-26 University Of Technology Sydney Immune-modulating agents and uses therefor
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
ES2936067T3 (es) 2014-05-27 2023-03-14 Univ Queensland IL-22 para uso en el tratamiento de trastornos metabólicos
FR3067226B1 (fr) * 2017-06-13 2021-10-08 Rossignol Lange Element de chaussure de ski

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567650A (en) * 1969-02-14 1971-03-02 Ncr Co Method of making microscopic capsules
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
IN167096B (show.php) * 1985-04-04 1990-09-01 Akzo Nv
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
EP0366058A3 (en) * 1988-10-27 1991-03-20 Abbott Laboratories Controlled-release delivery device, method for producing device, and method of using device

Also Published As

Publication number Publication date
AU5939394A (en) 1994-06-02
NL194637C (nl) 2002-10-04
ITMI911953A1 (it) 1993-01-15
PT98497B (pt) 1997-10-31
CH682715A5 (fr) 1993-11-15
PT98497A (pt) 1992-06-30
TNSN91067A1 (fr) 1992-10-25
AU649696B2 (en) 1994-06-02
FI913646L (fi) 1992-02-02
AU666808B2 (en) 1996-02-22
BE1004772A3 (fr) 1993-01-26
DK175756B1 (da) 2005-02-14
NL194637B (nl) 2002-06-03
NO912986L (no) 1992-02-03
NO912986D0 (no) 1991-07-31
DK141891D0 (da) 1991-07-31
IT1251788B (it) 1995-05-26
NL9101306A (nl) 1992-03-02
FI104149B1 (fi) 1999-11-30
MY107500A (en) 1995-12-30
MA22245A1 (fr) 1992-04-01
NZ238981A (en) 1992-11-25
SE9102249D0 (sv) 1991-07-26
FR2665360B1 (fr) 1995-02-10
HK33294A (en) 1994-04-22
OA09387A (fr) 1992-09-15
NO300158B1 (no) 1997-04-21
AU8146691A (en) 1992-02-06
SE9102249L (sv) 1992-02-02
ZA915565B (en) 1992-04-29
IN178446B (show.php) 1997-05-03
AT396425B (de) 1993-09-27
CA2048270A1 (en) 1992-02-02
FI104149B (fi) 1999-11-30
ES2046083A1 (es) 1994-01-16
ITMI911953A0 (it) 1991-07-15
FI913646A0 (fi) 1991-07-31
IE65124B1 (en) 1995-10-04
LU87982A1 (fr) 1992-04-15
DE4125542A1 (de) 1992-02-06
GR910100330A (en) 1992-08-31
GB9016885D0 (en) 1990-09-12
SE505734C2 (sv) 1997-10-06
KR920003962A (ko) 1992-03-27
JPH05178740A (ja) 1993-07-20
GR1001512B (el) 1994-02-28
US5213812A (en) 1993-05-25
JP2818704B2 (ja) 1998-10-30
DK141891A (da) 1992-02-02
IE912700A1 (en) 1992-02-12
CA2048270C (en) 1997-02-25
FR2665360A1 (fr) 1992-02-07
ATA152591A (de) 1993-01-15

Similar Documents

Publication Publication Date Title
ES2046083B1 (es) Procedimiento para preparar composiciones de liberacion prolongada.
HRP20010463B1 (hr) Smjesa s kontroliranim otpuštanjem koja sadrži galantamin
AU7315301A (en) Compounds and compositions for delivering active agents
ES2031096T3 (es) Una composicion de implante mejorada a base de estradiol y metodo para su preparacion.
MX9700850A (es) Formulaciones y metodos para proporcionar anestesia local prolongada.
SE9003665D0 (sv) Morphine prodrugs
IL115721A0 (en) Methods and compositions for the modulation of cell proliferation and wound healing
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
BR0009893A (pt) Composição de cuidado com a pele; e uso de uma composição de cuidado com a pele
MX9705710A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
DE60129849D1 (de) Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
MXPA02008117A (es) Particulas de ceramica de liberacion controlada composiciones de estas, procesos de su preparacion y metodos de uso.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
HUP9702457A3 (en) Synergistic herbicidal compositions containing glufosinate and nitrodiphenyl ether derivatives as active ingredients and use thereof
IL115046A (en) Sprayable film-forming preparation for application to plants and the uses thereof
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DK0975334T3 (da) Biologisk nedbrydelige mikropartikler til langvarig frigivelse af terapeutiske midler
HUT52083A (en) Herbicidal compositions comprising cyclohexenone oxymetres as active ingredient and process for producing the active ingredients
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
WO2002015959A3 (en) Compounds and compositions for delivering active agents
AU8916198A (en) Composition, device and method of using
ATE281830T1 (de) Geschmacksneutrale pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
FD2A Announcement of lapse in spain

Effective date: 20110819